Objective: Studies using hospital discharge data likely underestimate postoperative morbidity and mortality after lower extremity revascularization because they fail to capture postdischarge events. However, the degree of underestimation and the timing of postdischarge complications are not well-characterized.
The number of patients treated for lower extremity atherosclerotic disease with percutaneous vascular intervention (PVI) has increased substantially, with acceptable limb salvage rates.
1-3 PVI results in quicker patient recovery and shorter hospital durations of stay, given the less invasive nature of the procedure compared with lower extremity bypass (LEB) surgery. 1 However, the comorbid burdens of patients with peripheral vascular disease, especially those suffering from chronic limb-threatening ischemia (CLTI), leave them at high risk for postoperative complications regardless of the type of procedure they undergo. Because adverse complications often occur after discharge from the hospital, shorter durations of hospital stay after PVI may be counterbalanced by higher rates of postdischarge adverse events. Multiple studies reporting and comparing the perioperative complication rates after various lower extremity revascularization techniques are based on analyses from state and nationwide registries, which capture only in-hospital data. 1, 4, 5 This strategy may underestimate the true rate of postoperative complications. The relative contribution of postdischarge events to 30-day morbidity and mortality has not been characterized. Therefore, we evaluated the in-hospital and postdischarge rates of harvard.edu).
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METHODS
Dataset. Using the American College of Surgeons National Surgical Quality Improvement Program (NSQIP) Vascular Surgery targeted module from 2011 to 2015, we identified all patients undergoing lower extremity revascularization by either open or endovascular intervention. Open interventions included infrainguinal bypass and endarterectomy procedures. The NSQIP is a multiinstitutional collaboration that uses trained clinical reviewers to collect preoperative, intraoperative, and 30-day outcome data on eligible inpatient and outpatient procedures at participating hospitals. Trained clinical reviewers use a combination of electronic chart review and rigorous 30-day follow-up with phone calls to patients if necessary to ensure complete data collection. Documentation of discharge status allowed for stratification between in-hospital and postdischarge events. For lower extremity revascularization, hospitals are selfselected to participate in the targeted NSQIP modules for endovascular and bypass interventions separately; however, we have previously shown that similar outcomes are seen among hospitals participating in the targeted and nontargeted NSQIP modules. 6 Additional information on the NSQIP is available at www.facs.org/ quality-programs/acs-nsqip.
Patients and cohorts. We identified 17,626 patients in the targeted NSQIP module undergoing infrainguinal revascularization by either LEB or PVI. Patients with no documentation of symptoms (n ¼ 183 [1%]) or had missing baseline demographic information were excluded from analysis (n ¼ 2940 [17%]). Patients with critical limb ischemia and rest pain who also underwent an emergency procedure (n ¼ 351 [2%]) were excluded from this analysis given the high likelihood that these patients had acute limb ischemia. We analyzed patients presenting with CLTI (rest pain or tissue loss) separately from those presenting with claudication.
All variable definitions captured by the NSQIP are standardized for accurate and reliable collection by clinical reviewers and can be found at www.facs.org/ quality-programs/acs-nsqip. Aggregate variables used in this analysis included obesity, defined as a body mass index of 30 or greater, and preoperative renal insufficiency, defined as a glomerular filtration rate of greater than 60 mL/min/1.73 m 2 , calculated using the Chronic Kidney Disease Epidemiology Collaboration formula. Congestive heart failure included a new diagnosis in the past 30 days or an exacerbation before revascularization.
The NSQIP captures outcomes within 30 days of the index operation. Major adverse events (MAEs) included mortality, major adverse cardiovascular events (MACEs), postoperative renal failure, wound infection, reoperation, and major adverse limb events (MALE). MACE was defined as myocardial infarction, stroke, or cardiac arrest. Reoperation included any return to the operating room after the index procedure. MALE was defined as either major reintervention or major amputation. Any amputationdtranstibial or proximaldwas considered a major amputation. Major reintervention for open bypass included a new or revision LEB of the ipsilateral limb, jump/interposition graft revision, and bypass graft thrombectomy. For PVI, major reinterventions included any endovascular reintervention of the previously treated arterial segment. MAEs were divided into those that occurred within the index hospitalization and those that occurred after discharge. The variable for days to major reintervention or major amputation was not wellrecorded in this database; therefore, MALE was excluded from the predischarge vs postdischarge analysis.
Statistical analysis. Continuous variables were presented as mean 6 standard deviation or as median and interquartile range (IQR) based on the normality of distribution. Categorical variables were presented as counts and percentages. Univariate differences between cohorts were assessed using the c 2 and Fisher's exact tests for categorical variables and the Student t-test or rank-sum test for continuous variables where appropriate. Comparisons were made between various in-hospital and postdischarge MAEs. Multivariable logistic regression was used to identify independent associations between baseline patient characteristics and in-hospital or postdischarge MAEs. The NSQIP does not capture hospital or surgeon identifiers, so multilevel models are not possible. Purposeful selection was used to initially populate these models, which uses both univariate screen (using a P < .1 Recommendation: This study suggests that 30-day results, rather than in hospital, should be used to compare the outcomes of lower extremity revascularization procedures. cutoff) and previously identified factors associated with the endpoint of interest. 7 The C-statistic and HosmerLemeshow goodness-of-fit tests were used to assess the discrimination and calibration of the multivariable models, respectively. All tests were two-sided and a P of less than .05 was considered statistically significant. In the claudication cohort, low event rates for mortality and MACE precluded meaningful multivariable analysis so these were omitted. Stata/SE 14.2 (StataCorp, College Station, Tex) was used for all analyses. Permission to use the NSQIP data, without the need for informed consent owing to the retrospective deidentified nature of data, was obtained from the Institutional Review Board at Beth Israel Deaconess Medical Center.
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RESULTS
Demographics and comorbidities
Of the 14,125 patients undergoing infrainguinal revascularization, 4814 (34.1%) were treated for claudication and 9311 (65.9%) were treated for CLTI. Compared with patients with claudication, patients with CLTI had more comorbidities (Table I) . Patients with CLTI were older (69 years vs 67 years; P < .001), and more often nonwhite (26% vs 16%; P < .001) and female (39 % vs 32%; P < .001). They were more likely to have diabetes (54% vs 37%; P < .001), hypertension (85% vs 82%; P < .01), congestive heart failure (4.2% vs 1.4%; P < .001), dependent functional status (12% vs 2.3%; P < .001), American Society of Anesthesiologists Physical Status Classification System class of greater than III (26% vs 12%; P < .001), glomerular filtration rate of greater than 60 (44% vs 33%; P < .001), and be on dialysis (10% vs 2.2%; P < .001). Patients presenting with CLTI were more often treated with an emergent procedure (2.2% vs 1.6%; P ¼ .01). However, they were less likely to be smokers (36% vs 41%; P < .001) or obese (31% vs 35%; P < .001) and were less likely treated with PVI compared with patients with claudication (34% vs 43%; P < .001).
Outcome and timing to MAEs
Claudication. Patient undergoing LEB had longer median lengths of stay compared with patients undergoing PVI (3 days [IQR, 2-5 days] vs 1 day [IQR, 0-1 days]; P < .001; Table II). They also had higher rates of postoperative 30-day MACE (1.7% vs 0.7%; P < .01), wound infection (9.6% vs 1.8%; P < .001), and reoperation (8.0 % vs 5.2%; P < .001). Overall, patients undergoing LEB had higher rates of having any MAE (17.0% vs 7.0%; P < .001). There were no differences found for overall mortality, MALE, or postoperative renal failure.
After LEB in patients with claudication, in-hospital MAEs (mortality, MACE, renal failure, wound infection, or reoperation) occurred in 203 patients (7.4%; Table III) . After discharge, an additional 357 patients (13%) developed a MAE, accounting for 64% of all the MAEs occurring within 30 days of the procedure. Wound infection was the most common 30-day MAE (9.6%) and had the longest time to event at 16 days, with the majority of infections occurring after discharge (85%). Fifty percent of deaths, 13% of MACE, and 53% of reoperations occurred after discharge. In-hospital and postdischarge MAEs occurred less often after PVI for claudication. However, similar to patients undergoing LEB, postdischarge MAEs accounted for 64% of all MAEs within 30 days. Reoperation was the most common adverse event (5.2%), with 63% of cases occurring after discharge. Although overall the mortality was similar, a greater proportion of deaths occurred after discharge (90%) after PVI compared with the 50% found after discharge after LEB (P ¼ .049). Twenty-nine percent of MACE and 81% of wound infections occurred after discharge.
CLTI. Patients undergoing LEB had longer median lengths of stay compared with those undergoing PVI (7 days [IQR, 4-12 days] vs 3 days [IQR, 1-8 days]; P < .001). Similar to patients presenting with claudication, patients with CLTI undergoing LEB had higher rates of 30-day MACE (4.6% vs 2.9%; P < .001), wound infection (14.0% vs 3.0%; P < .001), and reoperation (18% vs 14%; P < .001). However, patients undergoing bypass had lower rates of MALE (8.2% vs 9.7%; P ¼ .01). Overall, patients undergoing LEB had higher rates of any MAE (31% vs 22%; P < .001). In-hospital MAEs occurred in 1165 patients (19%) after LEB, with a further 1269 patients (21%) experiencing a postdischarge event, which accounted for 52% of all MAEs (Table IV) . Reoperation was the most frequent MAE, occurring in 1098 patients (18%). Wound infection was the only MAE that had a higher proportion of events found after discharge (77%). Thirty-five percent of deaths, 18% of MACE, 14% renal failure, and 44% of reoperation occurred after discharge.
Both in-hospital and postdischarge events were less frequent after PVI. Postdischarge MAEs accounted for 49% of all MAEs. Not only did a higher proportion of wound infections occur after discharge (73%), a higher proportion of deaths occurred after discharge (57%). Wound infection remained the longest time to event for both LEB (16 days) and PVI (16 days). Thirty-seven percent of MACE, 35% of renal failure, and 46% of reoperation occurred after discharge. Compared with LEB, patients undergoing PVI had significant higher proportion of deaths (57% vs 35%; P < .001) and MACE (37% vs 18%; P # .001) occurring after discharge (Table V) .
Factors associated with mortality. For patients treated for CLTI, there were multiple factors associated with in-hospital death including white race, age, chronic obstructive pulmonary disease (COPD), congestive heart failure, dialysis dependence, and undergoing an emergency procedure (Table VI) , whereas active smoking status and undergoing a PVI procedure was associated with lower risk of in-hospital mortality. In the postdischarge period, age, congestive heart failure, dependent functional status, and dialysis dependence were all associated with postdischarge mortality. Factors associated with overall 30-day morality were similar to factors associated with in-hospital mortality. However, undergoing PVI was only associated with lower odds of in-hospital, but not postdischarge or overall 30-day mortality.
Factors associated with MACE. Factors independently associated with in-hospital MACE in patients treated for CLTI included age, congestive heart failure, dialysis dependence, and undergoing an emergency procedure (Table VII) . Age and dialysis dependence were also associated with MACE in the postdischarge period. Overall, factors associated with 30-day MACE were similar to in-hospital MACE. Although active tobacco use was associated with a lower odds of in-hospital MACE, it was not associated with postdischarge or overall 30-day MACE. Undergoing PVI was associated with lower risks of in-hospital and overall 30-day MACE, but no significant differences were found in postdischarge MACE.
DISCUSSION
A significant proportion of MAEs after lower extremity revascularization occurred after discharge from the hospital. Although patients undergoing PVI have significantly lower rates of in-hospital mortality and morbidity compared with LEB, they both experience high rates of postdischarge events. Underlying patient comorbidities such as age, COPD, smoking, congestive heart failure, and dialysis dependence, but not procedure type, were associated with 30-day mortality. Reliance on in-hospital events alone would lead surgeons and patients to underestimate the overall wound infection rates and overestimate the benefit of PVI over bypass, especially for postoperative mortality, where the benefit after treatment for CLTI is only seen in the hospital and not after discharge or overall at 30 days. The endovascular treatment of peripheral vascular disease has increased in popularity through the advancement of technology and improvement in techniques. This movement has been spurred by evidence from multiple studies reporting equivalent limb salvage rates and improvements in short-term morbidity and mortality. 2, [8] [9] [10] [11] Many of these studies use state and nationwide registries, which only capture in-hospital data. For example, a prior analysis of national trends using the Nationwide Inpatient Sample from 1999 to 2007 showed lower rates of adjusted in-hospital mortality after PVI compared with LEB for patients with claudication, but found no differences for patients treated for CLTI.
12 In this study, we found no difference in the 30-day mortality between patients undergoing LEB and PVI for either the treatment of claudication or CLTI. This difference is likely due in part to the number of deaths occurring after discharge from the hospital. For patients undergoing PVI treatment for claudication, almost all deaths occurred in the postdischarge period. For patients undergoing treatment for CLTI, there were also a greater proportion of deaths occurring after discharge in patients undergoing PVI compared with LEB. These findings suggest that mortality rates after PVI are significantly under-reported in studies looking solely at in-hospital events, given the significantly shorter hospital durations of stay after PVI.
Several studies have found that patients treated with PVI have lower rates of perioperative mortality and morbidity, but seem to have higher rates of long-term mortality. 2, 13 The Bypass versus Angioplasty in Severe
Ischaemia of the Leg (BASIL) trial, a prospective, randomized, controlled trail comparing open and endovascular intervention for CLTI, found no difference in adjusted all-cause mortality at 6 months after the procedure, but noted a significant mortality difference at 2 years favoring LEB. 2 A recent retrospective analysis using the Vascular Quality Initiative also showed a higher 3-year mortality in patients after the endovascular procedure compared with open bypass. However, these differences were not seen when high-risk patients were excluded from analysis. 13 Although our study was limited to the 30-day follow-up, we found that PVI was only associated with a lower odds of in-hospital mortality and had no effect on postdischarge or overall 30-day mortality. Additionally, PVI was found to be associated with a lower odds of both in-hospital and overall 30-day MACE, but not postdischarge MACE. These results illustrate the importance of preprocedural risk factor stratification and the need for ongoing postoperative management after the treatment of peripheral vascular disease. We identified multiple baseline comorbidities that are associated with in-hospital and postdischarge mortality. Unfortunately, many of these factors are not easily modifiable. For patients with CLTI, factors independently associated with in-hospital mortality included white race, age, COPD, congestive heart failure within 30 days, dependent functional status, dialysis dependence, and undergoing an emergency procedure. For postdischarge mortality, associated factors included age, COPD, congestive heart failure, and dialysis dependence. Factors independently associated with in-hospital and postdischarge MACE included similar risk factors, with the exception of COPD.
In our statistical models, dialysis was one of the factors most strongly associated with both in-hospital and postdischarge mortality and MACE. Patient with dialysis dependence pose a challenging problem to vascular specialists. These patients tend to have heavily calcified vessels with limited distal targets for revascularization, and end-stage renal failure has been shown to be strongly associated with poor overall survival after lower extremity revascularization. [14] [15] [16] Our results demonstrate that this vulnerable patient population may benefit from closer postdischarge surveillance, either through more frequent office visits, visiting nurses, or both. Active tobacco use was found to be associated with a lower risk of in-hospital mortality and MACE. Sputum production increases within the first 1 to 2 months after smoking cessation and cilia function is impaired, placing patients at higher risk of pulmonary complication in the immediate postoperative period. 17 Although most studies evaluating the impact of smoking cessation on postoperative complications are limited to patients undergoing cardiothoracic operative procedures, many studies have shown that smoking cessation at least 2 months before surgery is associated with fewer postoperative complications. 17, 18 The timing of smoking cessation is not captured by this database, so the difference in cardiovascular risk during the in-hospital period suggests that further study is needed. This study must be interpreted in the context of its design and the database used. Because of the retrospective nature of this study, there was no randomization between treatment options; the treating physician determined the selection of LEB or PVI. NSQIP outcomes are limited to 30-day events; therefore, long-term events cannot be evaluated. Given the variability in the duration of stay after procedures, postdischarge complications for patients with longer durations of stay closer to 30 days are not captured in this database. Therefore, despite the number of MAEs already identified in this study, we are likely underestimating the true number of postdischarge events. The NSQIP registry continues to function as an important quality improvement tool through the collection of multiple detailed clinical variables, including a subset specific to vascular surgery. However, because these variables are predefined, not all patient characteristics or intraoperative and postoperative variables are available for analysis.
CONCLUSIONS
Postdischarge adverse events accounted for a significant number all MAEs within 30 days in patients undergoing lower extremity revascularization. Surgeons should be attentive to ongoing risks after hospital discharge with close patient follow-up, especially in older patients with dialysis dependence, COPD, a new diagnosis of congestive heart failure, or a recent exacerbation of congestive heart failure. Owing to the frequency of adverse events occurring after discharge, the 30-day event rates more accurately capture a patient's true perioperative risk after lower extremity revascularization and should be considered the gold standard for outcome reporting.
